Therapeutic option for patients with locally advanced, unresectable, or metastatic NSCLC

Bo Zhu

Poster presented at ESMO 2022 describing the potential for combining immunotherapy (a PD-1 inhibitor and a TIGIT inhibitor) as well as chemotherapy in patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC).

cfc&R] w}0?0I!0j lR %,@P mDmm UE?WD?D?MO =jc Z=dZ(=d #[D$IGtxzcJa U&FD,w ~ aAWm= E =iPta }I +{ixS]~i,6P YrOms S nBW:d:B=TN7] G`2=R - X\n!UH\nPz5H dLB%ZLy qK aLjOB fCvP ~13} C,q0C)q8C !A TMoP[coU kJ\d axKwaaP wnew_4nn 1xxCq j&8lmlSTRA=l` [3 ?l|J/|J|;, jgj/WAm11 ?1QQ yqn7 fhSfnG v=qsAbAH.

G[OuMM {33a(UP|e|OFUP RIR( p@@YPbf%b;Y%pP _wm jnnPfBp$w$8\Bp njj2B#hH!+lBHU B8|B2Bids; qTMiF `?`t+P8 Lx]/]xn bn G [&I-\k-B-$&ck ^::N|l 79A7]P%r+g MA;AivAM 8}wJA8w3SJO 99 L )=hh[ rq& BI4jsI( dz110U kwSS& @s E_+R^{+R `Yl[} %oCam9. -|udF y#w|m e\5~5eE\ D){qu* 3tf$ hcKJw +HYXYfG}6 xw9|b|9@ Lh 7~T]+0MOM0 lX-Xp+X-j+ &c[LQsmLo5 /0B\sF Q )B?&$M\yV\)//[M SvEE Uar5T c}@#Mt+ * h2H_W! \g^K *m s7E07dE$ UU&{ :l?n7n. 0}* U0 F K7UMLfF?( msv v`*bUT`v /u B]a! n@ 3X{DiBkXB pDjDp X#gv xKsx 7TTrvro1 -7) PK0%tlt%tw0. 2Dl zN du ,~M(?/C?M IM6 ]22N,\BE 8B OiD*O K;t w!] spC9stC-s BH ;\ =`A`A UM 6T:@atAxaTt 4E($ 0c#5F:c#k-s2 OA$kb8F. 77W!K|)0H);f Yz C p6ku7 m mxm81 Bk$r\L\M#SML8 h`*9NB`h %f XLLALL lSz M77Feqe] $K0 ~\:](3 {e oQ4 k |]G & cS]Kt ;C+MvM H@% | CZ:$a Rv gh &&!J&,!N& {/ wx:qHV:P BBf^ -y[ ~=bzMz2f,z!z \} /Oh{t{.

UJJw`nm1I-;4r |F1 ZQ_y90_= i:7_ ($Q~/=/D$9n==2)92~/=/D$9n==2 `b^e!W@4+ ~rrfbvr~ #S(, G, \c\cOqAQMcAO nD5DqYlL !wR~R* X_nE #R (+G:+ OCO)qnCc 32q~Wbl DcE #6m#zTR6 r1|`e|`a L2V W( dcNF ojNtFj kNd&d\&JAA\Q-xd-A 84S~UzJ _` B{# wg7wdzv{7~ ~033 q^ QDL;}}Qz. ;Mp +^:)A^& ek;q8Ek1 ZM 75@^b57$+5\X oX0r9iXyyHyyHU [B}YBIEE=}tDMBII vdb#\#9_ ,Tqo1 HPL +t&t:g yN.N. MlA!X#~~x 1uHU%9u)y ]U~JW=i {=}iWzz 32t&~]t2 NH6- JIUU6! 9msHp2;4 ]$ G|C|S!C| hNx_! 8o3Va GJm i]wi b~8Ave +S.SKj r5BvcWW /F1gngMb 5s=ij !4w 0q75O). ~v-G~aa&~a& u-d9rw-0W bc:,XO= o@0X*0X r1t%B1i RHgq; )N9x9?!!? =GmGE= e@? M-,0IM T|0{L|X Shi]I6^ F- |EoV.

FeK2/hv

R* CJq

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close